Hyperthermic intraperitoneal chemotherapy hipec

Results 141 to 150 of about 490,601 (215)

Perfusate Flow Rate: An Overlooked Factor in Hyperthermic Intraperitoneal Chemotherapy (HIPEC)? [PDF]

Ann Surg Oncol
Theile D, Czock D.
europepmc +1 more source

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Ovarian Cancer Recurrence. A Review

Abstract Ovarian cancer is the first cause of death among gynecological malignancies with a high incidence of relapse in the first 3 years after initial operation. The 3 most common cause of relapse is the chemoresistance of the tumor, the biological behavior of the tumor and the third is the inappropriate surgical excision.
openaire +2 more sources

CHIPOR, HORSE, and beyond: unraveling the role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. [PDF]

J Gynecol Oncol
Lim MC.
europepmc +1 more source

Hyperthermic intraperitoneal chemotherapy (HIPEC) increases risk of local anesthetic systemic toxicity (LAST). [PDF]

Saudi J Anaesth
Tsuchiya M, Takesada H, Mizutani K.
europepmc +1 more source

Reliability of bioreactance and pulse power analysis in measuring cardiac index during cytoreductive abdominal surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). [PDF]